DR. LYLE PETERSEN, M.D.
Osteopathic Medicine at Maren Cv, Fort Collins, CO
License number
Colorado 035729
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1209 Maren Cv, Fort Collins, CO 80525
Phone
(970) 221-6428
Personal information
See more information about LYLE PETERSEN at radaris.comName
Address
Phone
9348 Granzella Rd, Morrison, CO 80465
1119 Maren Cv, Fort Collins, CO 80525
1170 S Eaton Cir APT 1C, Castle Rock, CO 80104
4900 Boardwalk Dr, Fort Collins, CO 80525
1119 Maren Cv, Fort Collins, CO 80525
Organization information
See more information about LYLE PETERSEN at bizstanding.comLyle Petersen MD
1119 Maren Cv, Fort Collins, CO 80525
Industry:
Internist
Phone:
(970) 221-6428 (Phone)
Lyle Robert Petersen
Professional information
Lyle Petersen, Fort Collins CO
Specialties:
Internist
Address:
3150 Rampart Rd, Fort Collins, CO 80521
3156 Rampart Rd, Fort Collins, CO 80521
3156 Rampart Rd, Fort Collins, CO 80521
Education:
University of California San Francisco, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Dr. Lyle Petersen - MD (Doctor of Medicine)
Hospitals:
3150 Rampart Rd, Fort Collins 80521
3150 Rampart Rd, Fort Collins 80521
3150 Rampart Rd, Fort Collins 80521
Education:
Medical Schools
University of California At San Francisco
Graduated: 1981
University of California At San Francisco
Graduated: 1981
Production Of Ospa For Lyme Disease Control
US Patent:
2011011, May 19, 2011
Filed:
Apr 9, 2009
Appl. No.:
12/936499
Inventors:
Ning Huang - Davis CA, US
Deshui Zhang - Woodland CA, US
Somen Nandi - Sacramento CA, US
Lyle Robert Petersen - Fort Collins CO, US
Deshui Zhang - Woodland CA, US
Somen Nandi - Sacramento CA, US
Lyle Robert Petersen - Fort Collins CO, US
International Classification:
A61K 39/02, A01H 5/00, A01H 5/10, C12P 21/00, C12N 15/63, A61P 37/04, A61P 31/04
US Classification:
4242341, 800298, 8003202, 8003201, 800320, 8003203, 435 691, 4353201
Abstract:
The present invention relates, generally, to the production of one or more OspA proteins in plant cells. Heterologous DNA comprising genes encoding one or more desired OspA protein(s) are introduced into plant cells. The one or more OspA protein(s) can be recombinantly-produced in the plant cells, optionally purified from the plant cells, and used as an oral vaccine to prevent the transmission of Lyme disease, particularly by animal vectors. The recombinantly-produced OspA protein(s) can be provided in oral and parenteral formulations. The present invention also relates to oral administration of OspA protein(s) to vaccinate against Lyme disease. The OspA protein(s) may be provided in a dosage form that is suitable for oral administration as a vaccine to prevent an animal from developing Lyme disease after exposure to a source of